The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

In commemoration of World Cancer Day 2025, themed “United by Unique,” Betty Anyanwu-Akeredolu, widow of former Ondo State ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

A MUM-of-two diagnosed with terminal breast cancer after her second round of IVF has written cards for both of her children ...

The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million vaccine plant in Liverpool, but insisted the business case did not stack up ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...